Systemic lupus erythematosus biomarkers: the challenging quest

Area of Science:

• Immunology
• Rheumatology
• Biomarker Discovery

Background:

• Systemic lupus erythematosus (SLE) is a complex autoimmune disease involving innate and adaptive immune system activation.
• Characterized by autoantibody production against cellular components, SLE exhibits significant heterogeneity in immune dysregulation.
• Past research has focused on blood biomarkers, yielding incremental understanding but no definitive predictive markers.

Purpose of the Study:

• To highlight the ongoing challenges in identifying reliable biomarkers for SLE disease activity and prediction.
• To emphasize the pursuit of novel therapeutic strategies targeting elevated SLE biomarkers.
• To underscore the critical role of emerging -omics technologies in advancing SLE research.

Main Methods:

• Review of decades of blood biomarker investigations in SLE.
• Analysis of clinical trial strategies aimed at inhibiting elevated SLE biomarkers.
• Leveraging new -omics technologies for biomarker and therapeutic discovery.

Main Results:

• No single biomarker has proven effective as a surrogate for SLE disease activity or prediction.
• Despite numerous clinical trials, effective therapeutics targeting SLE biomarkers remain elusive.
• The heterogeneity of immune dysregulation in SLE presents a significant challenge.

Conclusions:

• The quest for better surrogate biomarkers and successful therapeutics for SLE is ongoing.
• New -omics technologies are crucial for future advancements in SLE understanding and treatment.
• Continued research is necessary to overcome the complexities of SLE immune dysregulation.